相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Treatment-related Myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
Myron S. Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation
Franck Morschhauser et al.
BLOOD (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)
Benjamin D. Rosenbluth et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current treatment approaches for mantle-cell lymphoma
TE Witzig
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab
SJ Horning et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
H Borghaei et al.
SEMINARS IN NUCLEAR MEDICINE (2004)
Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
LI Gordon
SEMINARS IN ONCOLOGY (2003)
Efficacy and safety of Y-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
TE Witzig
SEMINARS IN ONCOLOGY (2003)
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
SM Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
